Amirsys Revenue and Competitors
Estimated Revenue & Valuation
- Amirsys's estimated annual revenue is currently $1.2M per year.
- Amirsys's estimated revenue per employee is $101,500
Employee Data
- Amirsys has 12 Employees.
- Amirsys grew their employee count by -8% last year.
Amirsys's People
Name | Title | Email/Phone |
---|
Amirsys Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.4M | 3 | -50% | N/A | N/A |
#2 | $0.5M | 7 | 0% | N/A | N/A |
#3 | $1M | 12 | 0% | N/A | N/A |
#4 | $6.7M | 51 | N/A | N/A | N/A |
#5 | $2M | 19 | 0% | N/A | N/A |
#6 | $25M | 157 | N/A | N/A | N/A |
#7 | $2.8M | 28 | N/A | N/A | N/A |
#8 | $0.2M | 3 | N/A | N/A | N/A |
#9 | $0.5M | 7 | 0% | N/A | N/A |
#10 | $0.4M | 5 | 0% | N/A | N/A |
What Is Amirsys?
Amirsys is a medical information systems provider that develops its own proprietary technology and content exclusively in the image-intensive areas of medicine and surgery. Our two co-founders, Dr. Anne Osborn and Dr. H. Ric Harnsberger, are among the best-known neuroradiologists in the world. In addition to our founders, our 150+ member author and luminary contributor team is a "who's who" of practice areas of radiology, pathology, surgery and other specialty fields. They are the key elements behind our motto "Names you know. Content you trust."® A number of our team members also advise many of the leading imaging and pathology equipment, PACS and RIS manufacturers.
keywords:N/AN/A
Total Funding
12
Number of Employees
$1.2M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Amirsys News
Honoraria: Amirsys. Matthew R. Cooperberg. Consulting or Advisory Role: Astellas Pharma, Dendreon, AstraZeneca, Bayer, Merck, Exact Sciences...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.3M | 12 | 0% | N/A |
#2 | $333.6M | 12 | -8% | N/A |
#3 | $2M | 12 | 9% | N/A |
#4 | $1M | 12 | 9% | N/A |
#5 | N/A | 12 | -29% | N/A |